Mei-Yun Zhang obtained her B.S. degree and her M.S. degree in science from China Agricultural University, Beijing, China, and her Ph.D. degree in natural science from Aachen University, Aachen, Germany. She joined Dr. Dimiter S. Dimitrov Laboratory at the National Cancer Institute (NCI) of the National Institutes of Health (NIH), USA, in 2000. After being trained as a Postdoc Fellow for two years, she was promoted to a Scientist and worked in the same laboratory for eight more years. She moved to Hong Kong in 2009 and became a Faculty Member of LKS Faculty of Medicine, The University of Hong Kong. She set up her own research group that currently includes one postdoc fellow, six Ph.D./D.Phil. students, and three research assistants. Her group research focuses are elucidation of mechanisms of the interplay of antibodies and viruses in humans, in particular, the highly mutable viruses, HIV-1, and influenza virus; development of antibody-based prophylactics and therapeutics for HIV/AIDS; neutralizing antibody-guided vaccine immunogen design for HIV/AIDS; development of antibody drugs for cancer diagnosis and therapy. Her major long-term goal is the development of clinically useful therapeutics and vaccines against infectious diseases and cancer based on human monoclonal antibodies. Dr. Zhang is an editorial board member for three journals. She has published over forty peer-reviewed journal articles and three book chapters. Dr. Zhang is a coinventor of four US patents, two EU patents, and several patent applications on antibodies. During her stay at NIH, she received Federal Technology Transfer Award for seven consecutive years.
Biography Updated on 31 March 2013